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HIGHLIGHTS 24 
 Antimalarial efficacy of a series of 26 investigational aminoquinolines was examined. 25 
 Two compounds with adamantane as a carrier cured 100% of infected mice.  26 
 Of which one had no in vitro effect against a chloroquine resistant Plasmodium strain. 27 
 Better in vivo than in vitro results suggest a role for the compound metabolites.  28 
 Adamantane aminoquinolines warrant further investigation.  29 
 30 
ABSTRACT 31 
 32 
Malaria remains a major disease of the developing world and globally the most important 33 
parasitic disease causing significant morbidity and mortality. Because of widespread resistance to 34 
conventional antimalarials including chloroquine (CQ), new drugs are urgently needed. We here 35 
report on the antimalarial efficacy, both in vitro and in vivo, of a series of aminoquinoline 36 
derivatives with adamantane or benzothiophene as a carrier. In vitro efficacy was evaluated by an 37 
LDH assay in cultures of a CQ-sensitive (3D7) and a CQ-resistant (Dd2) strain of Plasmodium 38 
falciparum. Of a series of 26 screened compounds, those 12 that exerted a growth inhibition rate 39 
of at least 50% were further examined in vitro, to determine the IC50 values, and in vivo. This 40 
way, even the four compounds that exhibited high IC50 values, were evaluated in vivo, in a 41 
modified Thompson test, in C57BL/6 mice infected with the P. berghei ANKA strain. However, 42 
another three compounds were eventually excluded due to toxicity in mice. All nine compounds 43 
examined in vivo prolonged survival of treated vs. untreated mice, four of which afforded at least 44 
a 60% survival. Most notably, two of these, both with the adamantane carrier, afforded complete 45 
cure (100% survival and parasite clearance). One of these, interestingly, had no in vitro effect 46 
(against the CQR strain). Better in vivo than in vitro results suggest a role for the compound 47 
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metabolites. The presented results point to adamantane as a carrier which enhances the 48 
antimalarial potential of aminoquinolines. 49 
 50 
Keywords: malaria, aminoquinolines, LDH assay, Thompson test, adamantane  51 
 52 
 53 
 54 
1. Introduction1 55 
  Malaria, caused by protozoan parasites of the Plasmodium genus, continues to be a 56 
major health problem of the developing world and globally the most important parasitic disease. 57 
Human infections are caused by five species of the genus: Plasmodium falciparum, P. vivax, P. 58 
ovale, P. malariae  and  P. knowlesi. Infection which results from the bite of an infected female 59 
Anopheles mosquito is characterized by blood and liver stages [1].  60 
The World Health Organisation estimated 214 million cases of malaria and 438,000 61 
deaths in 2015 [2], with most of the deaths caused by P. falciparum. Half of the global human 62 
population, residing in the tropical and subtropical areas, is estimated to be at a risk of infection, 63 
but even the other half is facing an increasing number of imported cases, resulting in deaths and  64 
health system burden in non-endemic countries and occasional secondary transmission in areas 65 
where malaria has long ago been eradicated [3].   66 
                                                          
1 1 Chloroquine (CQ); CQ-sensitive (CQS); CQ-resistant (CQR); food vacuole (FV); P. falciparum CQ resistance 
transporter (PfCRT); 4-aminoquinoline (AQ); 7-chloro-4-aminoquinoline (ClAQ); 3-fluoro-4-aminoquinoline 
(FAQ); 3-fluoro-7-chloro-4-aminoquinoline (FClAQ); 3-fluoro-7-chloro-2-aminoquinoline (FCl2AQ); dimethyl 
sulfoxide (DMSO); intraperitoneal (i.p.); per os (p.o.); lactate dehydrogenase (LDH); 50% inhibitory concentration 
(IC50); post infection (p.i.); real time PCR (qPCR) 
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The efficacy of the main conventional antimalarials, including chloroquine (CQ) and 67 
artemisinin, is hampered by widespread drug resistance. Coupled with the lack of an effective 68 
vaccine, this strongly emphasizes the urgent need for novel compounds to treat and prevent 69 
malaria [4, 5]. 70 
The mechanism of action of CQ, like all quinolones, involves activity against the 71 
erythrocyte forms of all Plasmodium species by preventing polymerization of heme through its 72 
selective accumulation in the parasite food vacuole (FV). CQ forms stable complexes with heme 73 
and its removal from FV is prevented by protonation [6, 7]. Mutations in the P. falciparum CQ 74 
resistance transporter (PfCRT) gene have a central role in CQ resistance. PfCRT is located in the 75 
FV membrane and, when mutated, increases CQ export from the FV and decreases its 76 
concentration inside the parasite [6, 8, 9].  77 
The aminoquinoline structure is very well known as a moiety useful for the design and 78 
development of new antimalarial agents [10, 11, 12, 13, 14]. Synthetic quinoline derivatives 79 
remain the most promising basis for discovery of new drugs [15], especially if they are effective 80 
against strains of Plasmodium resistant to CQ [16, 17], and 4-aminoquinoline derivatives 81 
continue to be the most sought after antimalarial agents for chemical modification [18]. Efforts to 82 
develop new aminoquinolines include overcoming CQ resistance by adding modifications at the 83 
ring or at the side chain, with the main aim of finding new ones, which are not recognized by 84 
mutant transporters and thus cannot be pumped out of the parasite FV.  85 
Recently, the synthesis of a series of aminoquinolines and tetraoxanes with demonstrated 86 
antiplasmodial activity, including activity against both the liver and blood stages, has been 87 
described [19]. We here report on further examination of the aminoquinoline series in different in 88 
vitro model systems, and provide further evidence for the complete curative effect observed in 89 
vivo by two compounds, despite, at least in one case, a poor in vitro effect. 90 
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 91 
2. Materials and methods 92 
2.1. Parasites 93 
Cultures of a chloroquine-sensitive (CQS) 3D7 and a chloroquine-resistant (CQR) Dd2 94 
strain of P. falciparum were maintained in human erythrocytes as described previously [20]. For 95 
in vitro drug assays, parasites were synchronized with 5% sorbitol, and ring-stage parasites were 96 
seeded in 96-well plates to achieve 2% parasitemia and 0.75% hematocrit.  97 
In vivo testing was performed using the Plasmodium berghei ANKA strain maintained 98 
through serial intraperitoneal (i.p.) passages in C57BL/6 mice. 99 
2.2. Mice 100 
Female C57BL/6 mice (Medical Military Academy Animal Research Facility, Belgrade), 101 
weighing between 19-21 g, were used. Groups of 4-6 animals were housed in the Institute for 102 
Medical Research Animal Facility under a natural photo-period, and offered drinking water and 103 
standard feed ad libitum.  104 
2.3. Compounds 105 
A total of 26 experimental aminoquinoline derivatives with adamantane or 106 
benzothiophene as a carrier synthesized at the Faculty of Chemistry, University of Belgrade, were 107 
examined (Table 1).  108 
According to the modifications at the aminoquinoline moiety structure, the compounds 109 
belonged to five groups as follows: 110 
1. 4-aminoquinoline - AQ (number of compounds, n=3) 111 
2. 7-chloro-4-aminoquinoline - ClAQ (n=6) 112 
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3. 3-fluoro-4-aminoquinoline - FAQ (n=2) 113 
4. 3-fluoro-7-chloro-4-aminoquinoline - FClAQ (n=8) 114 
5. 3-fluoro-7-chloro-2-aminoquinoline - FCl2AQ (n=7) 115 
For experimental use in vitro, the compounds were dissolved in dimethyl sulfoxide 116 
(DMSO) at a stock concentration of 50 mM. Compounds were further diluted in complete RPMI 117 
1640 culture medium so that the final DMSO concentration was ≤ 0.2%.  118 
Compounds further investigated in vivo were suspended in 0.5% hydroxyethylcellulose - 119 
0.1% Tween 80 and administered per os (p.o.).  120 
2.4. Experimental design  121 
All compounds were screened in vitro by the lactate dehydrogenase (LDH) assay adapted 122 
for Plasmodium [21], and those that at a defined concentration inhibited proliferation of either 123 
Plasmodium strain by at least 50% were titrated to obtain 50% inhibitory concentration (IC50) 124 
values and examined for in vivo efficacy. Prior to in vivo examination, compound toxicity was 125 
examined by treating uninfected mice with 160 mg/kg/day (the highest administered dose) of 126 
each compound for three consecutive days. A drug was considered nontoxic if mice did not 127 
develop any gross clinical symptoms (ruffled fur, lethargy or weight loss) during a 30-day 128 
observation period. Compounds determined to be nontoxic were evaluated for antimalarial 129 
efficacy at doses of 160 and 80 mg/kg/day. Compound efficacy was evaluated based on 130 
parasitemia over time and survival of the treated vs. untreated mice. Cure was defined as survival 131 
past day 31 p.i and complete clearance of parasitemia. Survival past day 31 p.i with residual 132 
parasitemia indicated survival without cure. If a compound did not afford survival but 133 
significantly prolonged time to death of treated vs. untreated mice (P<0.05), the effect was 134 
defined as prolonged survival. Finally, in case a compound cured mice in a dose of 80 135 
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mg/kg/day, efficacy was tested at lower doses, including 40, 20, and 10 mg/kg/day. Parasitemia 136 
was determined twice a week, starting from day 3 p.i. (immediately before treatment) and only 137 
mice in which parasitemia was detected were submitted to experimental treatment. Parasitemia 138 
was evaluated by microscopic examination of Giemsa stained thin blood smears prepared from 139 
mouse tail blood on an Axioscope 2+ (Zeiss) optical microscope at 1000X magnification, while 140 
parasite clearance was additionally confirmed in treated survivors by qPCR.  141 
2.5. In vitro examination of compound efficacy  142 
  In vitro testing was performed using a LDH assay. The compounds were first screened at 143 
a concentration of 500 nM, and those that showed a minimum of 50% growth inhibition of 144 
parasites of either strain (3D7 or Dd2) were further examined to obtain the IC50 value. Three 145 
independent experiments were performed for each compound, each with 3 replicates per 146 
condition. The assay was performed in flat-bottom 96-well microtiter plates. Briefly, compounds 147 
were tested at eight different concentrations, ranging from 256 nM to 2 nM, plated in a volume of 148 
100 µL. Parasites were plated into the wells while in the ring phase at 0.75% hematocrit and 2% 149 
parasitemia in a volume of 100 µL. Each well contained the compound and parasite culture in a 150 
final volume of 200µL. Following incubation at 37
o
 C for 48 hours in a Heracell 150i incubator 151 
(ThermoScientific, Waltham, MA, USA), the parasites were harvested and subjected to three 20-152 
minutes freeze-thaw cycles to resuspend the culture. Cultured erythrocytes without drug were 153 
used as the assay blank, while infected erythrocytes without drug were used as the assay control. 154 
CQ was used as the positive control for drug efficacy. To initiate the LDH reaction, 120 µL of the 155 
detection reagent mixture (Malstat and NBT/PES) was aliquoted into a new flat-bottom 96-well 156 
microtiter plate to which a 20 µL sample of each parasite culture was added. Color development 157 
of the LDH plate was detected by the Multiscan X (ThermoScientific, Waltham, MA, USA) 158 
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microplate reader at 620 nm after an hour incubation in the dark. All reagents used in the assay 159 
were purchased from Sigma-Aldrich Inc. (St. Louis, MO, USA).  160 
2.6. In vivo examination of compound efficacy  161 
Antimalarial activity in vivo was tested by a modified Thompson test [22]. Infected 162 
erythrocytes were obtained from the peripheral blood of a donor mouse infected with P. berghei. 163 
Mice were inoculated i.p. with 10
6
 infected erythrocytes, diluted in PBS to a total volume of 250 164 
μL total (day 0). Mice were treated with the investigational compounds once a day, for three 165 
consecutive days (days 3, 4 and 5 post infection (p.i.)). All compounds were administered p.o., at 166 
doses ranging from 160 mg/kg/day to 10 mg/kg/day in a total volume of 200 μL. Survival and 167 
parasitemia were monitored for 30 days p.i.. Parasitemia was evaluated by microscopic 168 
examination of thin blood smears.  169 
2.7. PCR  170 
Residual parasitemia was examined in the surviving mice by the real time PCR (qPCR) 171 
method adapted from Rougemont et al., based on the detection of Plasmodium species specific 172 
18S rRNA gene [23]. Briefly, mice alive past day 31 p.i. and with complete parasite clearance 173 
were sacrificed, and blood (300 - 500 μl) was sampled from the left ventricle of the heart. The 174 
liver was removed, rinsed with Dulbecco’s PBS and homogenized. DNA extraction was 175 
performed using 100 μl of blood and liver homogenate samples using the DNeasy blood and 176 
tissue kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Each PCR 177 
reaction contained 1X MaximaProbe qPCR Mastermix (Thermo Fisher Scientific, Waltham, MA, 178 
USA), 200 nM of each primer, 50 nM probe, 1U UNG (Thermo Fisher Scientific Waltham, MA, 179 
USA) and 3 μl template gDNA in a final volume of 20 μl. The PCR conditions were as follows: 180 
one holding step at 50°C for 2 min, one holding step at 95 °C for 10 min, then 45 cycles of 95 °C 181 
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for 15 s, 60 °C for 1 min. Samples with Ct values above 40 were considered negative. A positive 182 
(P. berghei DNA) and a negative (H2O) control were included in each run.  183 
2.8. Statistical analysis  184 
IC50 values were obtained using a sigmoidal dose-response model with the variable slope 185 
fitted to the results. Survival rates in each particular group were estimated by the Kaplan-Meier 186 
product limit method and compared by the log-rank (two curves) and log-rank test for trends 187 
(three or more curves) tests. The level of statistical significance was 0.05. Statistical analysis was 188 
performed using GraphPad Prism v. 5. 189 
 190 
3. Results 191 
A series of 26 aminoquinolines was examined in this work. Of these, 12 compounds 192 
inhibited proliferation of either the CQS or the CQR Plasmodium strain by at least 50%, while 193 
the remaining 14 compounds did not, so they were eliminated from further work. 194 
All 12 compounds were first assayed for toxicity. Four compounds (AQ2, AQ3, ClAQ3, 195 
ClAQ6) were shown to cause acute toxicity at a dose of 160 mg/kg/day, which eliminated them 196 
from further in vivo examination. However, due to chemical similarity with other members of the 197 
benzothiophene group, which were nontoxic even at the highest applied dose, one of the latter 198 
compounds, ClAQ3, although toxic at 160 mg/kg/day, was further tested for toxicity at 80 199 
mg/kg/day and found to be nontoxic at this dose. ClAQ3 was thus included in the in vivo 200 
examination (Table 2).  201 
A total of nine compounds (AQ1, ClAQ1, ClAQ2, ClAQ3, ClAQ4, ClAQ5, FAQ1, 202 
FClAQ1, FClAQ2) were subjected to in vivo testing. The results showed that, when administered 203 
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in doses of 160 and/or 80 mg/kg/day, all nine significantly prolonged survival of treated vs. 204 
untreated mice (P<0.05; Fig. 1, Fig. 2).  205 
Remarkably, three ClAQ compounds (ClAQ1, ClAQ4, ClAQ5) and one FClAQ 206 
compound (FClAQ1) (chemical structures presented in Table 3) afforded survival of 60-100% of 207 
treated mice past day 31. Of these, ClAQ4 and ClAQ5 afforded a 60-80% survival rate of 208 
infected mice, although not even the highest dose of either compound eradicated parasitemia in a 209 
single animal.  210 
But treatment with 160 and 80 mg/kg/day of the other two compounds, ClAQ1 and 211 
FClAQ1, afforded complete cure. All treated infected mice survived beyond d31 (Fig. 3, Fig. 4), 212 
and moreover, survival was associated with parasite clearance as determined by microscopic 213 
examination and by qPCR of murine blood and liver tissues after day 31. We thus next examined 214 
their effect at lower doses, which revealed a strong dose-dependent effect (P=0.0141 and 215 
P=0.0362 for ClAQ1 and FClAQ1, respectively), but did not afford survival. ClAQ1 is 216 
particularly interesting in this respect, as treatment with even the lowest dose (10 mg/kg) 217 
prolonged survival (P=0.0031). However, dose reduction resulted in persistence of parasitemia in 218 
all mice.  219 
On the other hand, an interesting observation with FClAQ1 was that although all mice 220 
treated with 40 mg per kg per day eventually succumbed to the infection, they were able to 221 
tolerate very high levels of parasitemia, which amounted up to 62% (ranging from 37.5 to 222 
62.4%). In contrast, the highest level of parasitemia observed with any other treatment regimen 223 
ranged from as low as 0.1 to not more than 13.9% (Table 4).  224 
Interestingly, the correlation between the in vivo and in vitro results appeared haphazard 225 
(Table 2). The four compounds with the highest in vivo efficacy did not show the best in vitro 226 
results i.e. the lowest IC50 values for both strains. For instance, ClAQ4 and ClAQ5, the two 227 
Page 10 of 26
 11 
 
compounds which afforded survival but not cure, had quite low IC50 values and by far the lowest 228 
ones against the CQR strain. In contrast, FClAQ1, which cured all infected mice (in two doses), 229 
had no in vitro effect against the CQR strain (>500 nM). On the other hand, AQ1, the single 230 
compound that had lower IC50 values than CQ against both strains, did not have remarkable in 231 
vivo efficacy. Of the remaining four compounds, which all significantly prolonged survival time 232 
of treated infected mice, even three had much higher IC50 values than CQ on both parasite strains 233 
(Table 2).  234 
4. Discussion 235 
We here presented the antimalarial efficacy of a series of investigational aminoquinoline 236 
compounds. Of the 12 that exhibited at least 50% of growth inhibition in parasite cultures, the 237 
efficacy of nine shown to be nontoxic in vivo was examined in a mouse infection model. When 238 
given in three daily doses of 160 or 80 mg/kg, all nine significantly prolonged survival compared 239 
to untreated controls, but most notably, four afforded survival of mice past day 31. Of these, 240 
compounds ClAQ4 and ClAQ5 afforded a high protection rate although with residual infection in 241 
mice that survived the observation period, while compounds ClAQ1 and FClAQ1 afforded cure 242 
(with parasite clearance) for 100% mice at doses of both 160 and 80 mg/kg/day. At the latter 243 
dose, the survival rate afforded by ClAQ1 and FClAQ1 was even superior to that of CQ. 244 
Furthermore, these two compounds showed significant activity in lower doses as well, of which 245 
ClAQ1 prolonged time to death (vs. untreated controls) even in a dose as low as 10 mg/kg.  246 
Several important observations arise from these data. To start, we have observed that the 247 
best in vivo effects did not correlate with in vitro efficacy. For instance, AQ1was the single 248 
compound that had lower IC50 values than CQ against both strains but its in vivo efficacy did not 249 
go beyond prolonging survival of infected treated mice. On the other hand, none of the three 250 
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examined compounds with fluorine on the aminoquinoline moiety had any effect of against the 251 
CQR strain in vitro, yet all significantly prolonged survival of infected treated mice, while 252 
FClAQ1 even afforded complete cure. Such discordance has been previously reported for some 253 
thiophene- and furan-based aminoquinolines synthesized by the same group [24]. The 254 
discrepancy between in vitro and in vivo effects suggests that the antimalarial efficacy of such 255 
compounds is due to their metabolites, rather than the compounds themselves.  256 
The second interesting observation was that, although FClAQ1 in lower doses did not 257 
afford survival, it allowed mice to survive remarkably high parasite burdens (37% to 62%), as 258 
opposed to the highest parasitemia of only 14%, seeming to be the survival limit by any other 259 
treatment. Importantly, this compound (designated compound 25 in [19]) has been shown to have 260 
significant activity in the plasmodial liver stage infection [19], where the presence of the fluorine 261 
atom at the C(3) position on the aminoquinoline moiety was attributed to the intrahepatocytic 262 
inhibition of parasite growth. The ability of mice treated with this compound to survive massive 263 
parasitemia may indicate its impact on the parasite pathogenicity/virulence. 264 
Importantly, the approach we took in this study, to examine all compounds which 265 
exerted at least 50% parasite growth inhibition in vitro, in parallel with their effects in an in vivo 266 
infection model, allowed us to observe a therapeutic potential that would have gone unnoticed 267 
had we chosen the usual approach to examine in vivo only those compounds with an IC50 lower 268 
than that of the control drug. This observation also suggests that there may have been drug 269 
candidates in the past that had been missed because of the approach. It is to be hoped that highly 270 
advanced techniques including high-throughput technologies will help leave such unfortunate 271 
events in the past. 272 
A look at the chemical structures of the four most effective compounds (Table 3) shows 273 
that the carrier in ClAQ4 and ClAQ5 is benzothiophene, while it is adamantane in the case of 274 
Page 12 of 26
 13 
 
ClAQ1 and FClAQ1. Since our results showed that both compounds with adamantane afforded 275 
cure of mice, it appears that the higher in vivo activity may be attributed to its use as a carrier. 276 
Among its many biological properties, adamantane has been shown to substantially increase drug 277 
solubility in lipophilic membranes and may thus increase the compound uptake [25].  278 
In summary, the presented results illustrate the enormous potential of aminoquinoline 279 
derivatives bearing an adamantane group as antimalarials whose metabolites and mechanisms of 280 
action warrant further investigation and put adamantane into the spotlight as a carrier which 281 
enhances the antimalarial effect of aminoquinolines. 282 
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Fig. 1. Effect of a 3-day treatment with 160 mg/kg/day of the investigational compounds on the 367 
survival of mice infected with P. berghei ANKA strain.  treatment days 368 
Fig. 2. Effect of a 3-day treatment with 80 mg/kg/day of the investigational compounds on the 369 
survival of mice infected with P. berghei ANKA strain.  treatment days 370 
Fig. 3. Effect of a 3-day treatment with ClAQ in the full dosage regimen on the survival of mice 371 
infected with P. berghei ANKA strain.  treatment days 372 
Fig. 4. Effect of a 3-day treatment with FClAQ1 in 3 dosage regimens (40, 80, 160 mg/kg) on the 373 
survival of mice infected with P. berghei ANKA strain.  treatment days 374 
 375 
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Table 1. Investigated compounds grouped according to the modifications at the aminoquinoline 376 
moiety 377 
GROUP COMPOUND ACRONYM 
Number 
in  
ref. [19] 
AQ 
N
1
-(1-adamantylmethyl)-N
3
-quinolin-4-ylbutane-1,3-diamine,  
C24H33N3 
AQ1 24 
N
1
-[2-(1-adamantyl)ethyl]-N
3
-quinolin-4-ylbutane-1,3-diamine AQ2 44 
N-(1-adamantylmethyl)-N-methyl-N'-quinolin-4-ylpropane-1,3-
diamine 
AQ3 
not 
previously 
published 
ClAQ 
N
1
-(1-adamantylmethyl)-N
3
-(7-chloroquinolin-4-yl)butane-1,3-
diamine 
ClAQ1 23 
N
2
-(1-adamantylmethyl)-N
1
-(7-chloroquinolin-4-yl)propane-1,2-
diamine 
ClAQ2 10 
N-(7-chloroquinolin-4-yl)-N'-[(5-fluoro-1-benzothiophen-3-
yl)methyl]propane-1,3-diamine 
ClAQ3 58 
N-(7-chloroquinolin-4-yl)-N'-[(5-fluoro-1-benzothiophen-3-
yl)methyl]butane-1,4-diamine 
ClAQ4 63 
N-(7-chloroquinolin-4-yl)-N'-[(6-fluoro-1-benzothiophen-3-
yl)methyl]propane-1,3-diamine 
ClAQ5 59 
N
1
-[2-(1-adamantyl)ethyl]-N
3
-(7-chloroquinolin-4-yl)butane-1,3-
diamine 
ClAQ6 36 
FAQ 
N
1
-(1-adamantylmethyl)-N
3
-(3-fluoroquinolin-4-yl)butane-1,3-
diamine 
FAQ1 26 
N
1
-[2-(1-adamantyl)ethyl]-N
3
-(3-fluoroquinolin-4-yl)butane-1,3-
diamine 
FAQ2 39 
FClAQ 
N
1
-(1-adamantylmethyl)-N
3
-(7-chloro-3-fluoroquinolin-4-yl)butane-
1,3-diamine 
FClAQ1 25 
N
4
-(7-chloro-3-fluoroquinolin-4-yl)-N
1
,N
1
-diethylpentane-1,4-
diamine 
FClAQ2 74 
N
1
-(1-adamantylmethyl)- N
2
-(7-chloro-3-fluoroquinolin-4-
yl)propane-1,2-diamine 
FClAQ3 20 
N
2
-(1-adamantylmethyl)-N
1
-(7-chloro-3-fluoroquinolin-4-
yl)propane-1,2-diamine 
FClAQ4 21 
N
1
-[2-(1-adamantyl)ethyl]-N
3
-(7-chloro-3-fluoroquinolin-4-
yl)butane-1,3-diamine 
FClAQ5 38 
N
1
-(1-adamantylmethyl)-N
4
-(7-chloro-3-fluoroquinolin-4-yl)pentane-
1,4-diamine 
FClAQ6 32 
N
1
-[2-(1-adamantyl)ethyl]-N
4
-(7-chloro-3-fluoroquinolin-4-
yl)pentane-1,4-diamine 
FClAQ7 45 
N'-(7-chloro-3-fluoroquinolin-4-yl)-N,N-diethylpropane-1,3-diamine FClAQ8 73 
FCl2AQ 
N
1
-(1-adamantylmethyl)-N
2
-(7-chloro-3-fluoroquinolin-2-
yl)propane-1,2-diamine 
FCl2AQ1 68 
N
1
-(1-adamantylmethyl)-N
3
-(7-chloro-3-fluoroquinolin-2-yl)butane-
1,3-diamine 
FCl2AQ2 69 
N
1
-[2-(1-adamantyl)ethyl]-N
3
-(7-chloro-3-fluoroquinolin-2-
yl)butane-1,3-diamine 
FCl2AQ3 71 
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N
1
-(1-adamantylmethyl)-N
4
-(7-chloro-3-fluoroquinolin-2-yl)pentane-
1,4-diamine 
FCl2AQ4 70 
N
1
-[2-(1-adamantyl)ethyl]-N
4
-(7-chloro-3-fluoroquinolin-2-
yl)pentane-1,4-diamine 
FCl2AQ5 72 
N
4
-(7-chloro-3-fluoroquinolin-2-yl)-N
1
,N
1
-diethylpentane-1,4-
diamine 
FCl2AQ6 76 
N'-(7-chloro-3-fluoroquinolin-2-yl)-N,N-diethylpropane-1,3-diamine FCl2AQ7 75 
 378 
 379 
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Table 2. Antimalarial effect of experimental aminoquinolines examined in vitro and in vivo 380 
  
 
In vitro (LDH assay) In vivo (Thompson test) 
GROUP COMPOUND 
3D7 
(geomeans, 
 nM) 
Dd2 
(geomeans,  
nM) 
TOXICITY 
160 
mg/kg/day 
TREATMENT 
DOSE 
(mg/kg/day) 
EFFECT on d31 p.i. 
  IC50 IC50    
AQ 
AQ1 14.08 118.2 NT 80 prolonged time to death* (P=0.0031) 
AQ2 99.86 195.3 T   
AQ3 67.33 223.0 T   
ClAQ 
ClAQ1 34.75 58.4 NT 
160, 80
 
100% cure  
40, 20, 10 
prolonged time to death* 
(P=0.0031, 0.0067, 0.0031)
 
ClAQ2 142.70 >500 NT 80 prolonged time to death* (P=0.0031) 
ClAQ3 43.48 34.8 T 80 prolonged time to death* (P=0.0067) 
ClAQ4 32.53 13.7 NT 
160
 
75% survival** (P=0.0067) 
80 80% survival** (P=0.0031) 
ClAQ5 34.13 16.7 NT 160 60% survival** (P=0.002) 
ClAQ6 67.07 35.9 T   
FAQ FAQ1 185.38 >500 NT 80 prolonged time to death* (P=0.0290) 
FClAQ 
FClAQ1 41.13 >500 NT 
160, 80
 
100 % cure  
40
 
prolonged time to death*(P=0.0031) 
20, 10 NS (P>0.05)
 
FClAQ2 145.36 >500 NT 160 prolonged time to death* (P=0.0020) 
CONTROL CQ 18.74 249.1 NT 160 100% cure  
AQ : 4-aminoquinoline ; ClAQ : 7-chloro-4-aminoquinoline ; FAQ : 3- fluoro-4-aminoquinoline ; FClAQ : 3- fluoro-7-chloro-4-aminoquinoline ; 381 
AQ1: N
1
-(1-adamantylmethyl)-N
3
-quinolin-4-ylbutane-1,3-diamine; AQ2: N
1
-[2-(1-adamantyl)ethyl]-N
3
-quinolin-4-ylbutane-1,3-diamine; AQ3: 382 
N-(1-adamantylmethyl)-N-methyl-N'-quinolin-4-ylpropane-1,3-diamine; ClAQ1: N
1
-(1-adamantylmethyl)-N
3
-(7-chloroquinolin-4-yl)butane-1,3-383 
diamine; ClAQ2: N
2
-(1-adamantylmethyl)-N
1
-(7-chloroquinolin-4-yl)propane-1,2-diamine; ClAQ3: N-(7-chloroquinolin-4-yl)-N'-[(5-fluoro-1-384 
benzothiophen-3-yl)methyl]propane-1,3-diamine; ClAQ4: N-(7-chloroquinolin-4-yl)-N'-[(5-fluoro-1-benzothiophen-3-yl)methyl]butane-1,4-385 
diamine; ClAQ5: N-(7-chloroquinolin-4-yl)-N'-[(6-fluoro-1-benzothiophen-3-yl)methyl]propane-1,3-diamine; ClAQ6: N
1
-[2-(1-adamantyl)ethyl]-386 
N
3
-(7-chloroquinolin-4-yl)butane-1,3-diamine; FAQ1: N
1
-(1-adamantylmethyl)-N
3
-(3-fluoroquinolin-4-yl)butane-1,3-diamine;  FClAQ1: N
1
-(1-387 
adamantylmethyl)-N
3
-(7-chloro-3-fluoroquinolin-4-yl)butane-1,3-diamine;  FClAQ2: N4-(7-chloro-3-fluoroquinolin-4-yl)-N1,N1-diethylpentane-388 
Page 20 of 26
 3 
 
1,4-diamine; CQ: chloroquine; 3D7: P. falciparum CQ-sensitive strain; Dd2: P. falciparum CQ-resistant strain; IC50: 50% inhibitory 389 
concentration; T: toxic; NT: nontoxic; * vs. infected untreated (control) mice; **with residual parasitemia; NS: not significant 390 
 391 
 392 
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Table 3. Chemical structures of the most active investigational compounds 393 
COMPOUND CHEMICAL STRUCTURE 
ClAQ4 
S
F
NH
NH
N
Cl
 
ClAQ5 
S
NH NH
F
N
Cl 
ClAQ1 
N
NH NH
Cl  
FClAQ1 
N
NH NH
F
Cl  
 394 
 395 
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Table 4. Survival and parasitemia of P. berghei-infected mice treated with ClAQ1 and FClAQ1 at different doses  396 
COMPOUND 
mg/kg/day 
No. of mice 
dead on day 
No. of mice  alive and parasitemia (range, in %) at time point 
Mice 
alive on 
day 
31/total 
(% 
survival) 
Before 
treatment 
Day 7 Day 10 Day 14 Day 17 Day 21 Day 24 Day 28 
CQ 
160 - 
5 
(0.4-0.9) 
5 
(0) 
5 
(0) 
5 
(0) 
5  
(0) 
5 
(0) 
5  
(0) 
5 
(0) 
5/5  
(100) 
80 1/17, 1/18 
5 
(0.5-0.9) 
5 
(0) 
5 
(0) 
3 
(0) 
3 
 (0) 3 
(0) 
3 
 (0) 
3 
(0) 
3/5 
(60) 2  
(0.1-0.2) 
1  
(4) 
 ClAQ1 
  
160  - 
5 
(0.7-1.2) 
5 
(0) 
5 
(0) 
5 
(0) 
5 
(0) 
5 
(0) 
5 
 (0) 
5 
 (0) 
5/5 
(100) 
80 - 
5 
(0.4-0.5) 
5 
(0) 
5 
(0) 
5 
(0) 
5 
(0) 
5 
(0) 
5  
(0) 
5 
(0) 
5/5 
(100) 
40 
1/16, 2/17, 
2/18 
5 
(0.3-2.4) 
5 
(0) 
5 
(0) 
5 
(0.2-1.2) 
2 
(2.1-4.6) 
-   
0/5 
(0) 
20 
2/14, 1/15, 
1/18 
4 
(0.5-3.5) 
4 
(0) 
4 
(0.2-0.4) 
2 
(1-3.9) 
 
1 
(3.5) 
-   
0/4 
(0) 
10 
1/11, 3/13, 
1/15 
5 
(0.4-1.6) 
5 
(0.18-0.5) 
5 
(1.6-8.9) 
1 (4.3) -    
0/5 
(0) 
FClAQ1 
160 - 
4 
(0.3-0.5) 
4 
(0) 
4 
(0) 
4 
(0) 
4 
(0) 
4 
(0) 
4 
 (0) 
4 
(0) 
4/4 
(100) 
80 - 
6 
(0.3-1) 
6 
(0) 
6 
(0) 
6 
(0) 
6 
(0) 
6 
(0) 
6  
(0) 
6 
(0) 
6/6 
(100) 
40 
2/12, 1/21, 
1/23,1/24 
5 
(0.5-3) 
5 
(1-4.7) 
5 
(3.1- 16.3) 
3 
(5.6-23) 
3 
(30-52.4) 
2 
(37.5-62.4) 
- - 
0/5 
(0) 
20 2/7, 1/8, 1/14 4 2 1 -     0/4 
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(0.3-2.3) (3.8-4) (10) (0) 
10 
2/7, 1/8, 1/11, 
1/12 
5 
(0.6-2.3) 
3 
(2.3-5) 
2 
(3.2-13.9) 
-     
0/5 
(0) 
 397 
 398 
 399 
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Figure 1 400 
 401 
 402 
 403 
Figure 2 404 
 405 
 406 
  407 
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Figure 3 408 
 409 
 410 
 411 
 412 
Figure 4 413 
 414 
 415 
 416 
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